Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: Structural and functional versatility in target recognition

Cellular and Molecular Life Sciences

Volumn 70, Issue 21, 2013, Pages 3989-4008

  Wang, Feng ^a,b,c   Marshall, Christopher B ^a,b   Ikura, Mitsuhiko ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; CBP p300; Histone acetyltransferase (HAT); Protein protein interaction; Transcription factors; Transcriptional coactivator

Indexed keywords

3,5 DIMETHYLISOXAZOLE DERIVATIVE; ACYLTRANSFERASE INHIBITOR; ARYLSULFONAMIDE KCN1; C 646; CELL NUCLEUS RECEPTOR; CHETOMIN; CURCUMIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEPSIDE SEKIKAIC ACID; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; ICG 001; ISCHEMIN; ITAD; KG 501; LTK 14; NAPHTHOL AS E PHOSPHATE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG TARGETING; EPIGENETICS; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION; ZINC FINGER MOTIF;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; E1A-ASSOCIATED P300 PROTEIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EUKARYOTA;

EID: 84887111466     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1254-4     Document Type: Review

References (217)

1. Guarente L (1995) Transcriptional coactivators in yeast and beyond. Trends Biochem Sci 20(12):517-521. doi: S0968-0004(00)89120-3
2. Thomas MC, Chiang CM (2006) The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 41(3):105-178. doi: 10.1080/10409230600648736
3. Ptashne M, Gann A (1997) Transcriptional activation by recruitment. Nature 386(6625):569-577. doi: 10.1038/386569a0
4. Workman JL, Roeder RG (1987) Binding of transcription factor TFIID to the major late promoter during in vitro nucleosome assembly potentiates subsequent initiation by RNA polymerase II. Cell 51(4):613-622. doi: 0092-8674(87)90130-9
5. Horikoshi M, Hai T, Lin YS, Green MR, Roeder RG (1988) Transcription factor ATF interacts with the TATA factor to facilitate establishment of a preinitiation complex. Cell 54(7):1033-1042. doi: 0092-8674(88)90118-3
6. Zhou J, Zwicker J, Szymanski P, Levine M, Tjian R (1998) TAFII mutations disrupt Dorsal activation in the Drosophila embryo. Proc Natl Acad Sci USA 95(23):13483-13488
7. Meisterernst M, Roeder RG (1991) Family of proteins that interact with TFIID and regulate promoter activity. Cell 67(3):557-567. doi: 0092-8674(91)90530-C
8. Dynlacht BD, Hoey T, Tjian R (1991) Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell 66(3):563-576. doi: 0092-8674(81)90019-2
9. Kim YJ, Bjorklund S, Li Y, Sayre MH, Kornberg RD (1994) A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II. Cell 77(4):599-608. doi: 0092-8674(94)90221-6
10. Bednar J, Horowitz RA, Grigoryev SA, Carruthers LM, Hansen JC, Koster AJ, Woodcock CL (1998) Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc Natl Acad Sci USA 95(24):14173-14178
11. Naar AM, Lemon BD, Tjian R (2001) Transcriptional coactivator complexes. Annu Rev Biochem 70:475-501. doi: 10.1146/annurev.biochem.70.1.475
12. Spiegelman BM, Heinrich R (2004) Biological control through regulated transcriptional coactivators. Cell 119(2):157-167. doi: 10.1016/j.cell.2004.09. 037
13. Bannister AJ, Kouzarides T (1996) The CBP co-activator is a histone acetyltransferase. Nature 384(6610):641-643. doi: 10.1038/384641a0
14. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953-959. doi: S0092-8674(00)82001-2
15. Shiama N (1997) The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol 7(6):230-236. doi: 10.1016/S0962-8924(97)01048-9
16. Kalkhoven E (2004) CBP and p300: HATs for different occasions. Biochem Pharmacol 68(6):1145-1155. doi: 10.1016/j.bcp.2004.03.045
17. Whyte P, Williamson NM, Harlow E (1989) Cellular targets for transformation by the adenovirus E1A proteins. Cell 56(1):67-75. doi: 0092-8674(89)90984-7
18. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM (1994) Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 8(8):869-884
19. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365(6449):855-859. doi: 10.1038/365855a0
20. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH (1994) Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370(6486):223-226. doi: 10.1038/370223a0
21. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J, Montminy M (1994) Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370(6486):226-229. doi: 10.1038/370226a0
22. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM (1999) Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13(1):64-75
23. De Guzman RN, Liu HY, Martinez-Yamout M, Dyson HJ, Wright PE (2000) Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol 303(2):243-253. doi: 10.1006/jmbi.2000.4141
24. Parker D, Ferreri K, Nakajima T, LaMorte VJ, Evans R, Koerber SC, Hoeger C, Montminy MR (1996) Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol Cell Biol 16(2):694-703
25. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG (1999) Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 274(48):34186-34195
26. Lin CH, Hare BJ, Wagner G, Harrison SC, Maniatis T, Fraenkel E (2001) A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. Mol Cell 8(3):581-590. doi: S1097-2765(01)00333-1
27. Demarest SJ, Martinez-Yamout M, Chung J, Chen H, Xu W, Dyson HJ, Evans RM, Wright PE (2002) Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 415(6871):549-553. doi: 10.1038/415549a
28. Ragvin A, Valvatne H, Erdal S, Arskog V, Tufteland KR, Breen K, AM OY, Eberharter A, Gibson TJ, Becker PB, Aasland R (2004) Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. J Mol Biol 337(4):773-788. doi: 10.1016/j.jmb.2004.01.051
29. Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. Oncogene 23(24):4225-4231. doi: 10.1038/sj.onc.1207118
30. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, Luscher B (2003) Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 4(5):484-490. doi: 10.1038/sj.embor.embor821
31. Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S (1996) CBP as a transcriptional coactivator of c-Myb. Genes Dev 10(5):528-540
32. Bannister AJ, Oehler T, Wilhelm D, Angel P, Kouzarides T (1995) Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 11(12):2509-2514
33. Bannister AJ, Kouzarides T (1995) CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J 14(19):4758-4762
34. Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18(18):5061-5072. doi: 10.1093/emboj/18.18.5061
35. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89(7):1175-1184. doi: S0092-8674(00)80304-9
36. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387(6635):823-827. doi: 10.1038/42981
37. Nasrin N, Ogg S, Cahill CM, Biggs W, Nui S, Dore J, Calvo D, Shi Y, Ruvkun G, Alexander-Bridges MC (2000) DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. Proc Natl Acad Sci USA 97(19):10412-10417. doi: 10.1073/pnas.190326997
38. So CW, Cleary ML (2002) MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol Cell Biol 22(18):6542-6552
39. So CW, Cleary ML (2003) Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 101(2):633-639. doi: 10.1182/blood-2002-06- 1785
40. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr (1996) Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci USA 93(26):15092-15096
41. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM (1996) Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 383(6598):344-347. doi: 10.1038/383344a0
42. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM (1996) An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93(23):12969-12973
43. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L (1998) Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 17(22):6573-6586. doi: 10.1093/emboj/17.22.6573
44. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM (2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97(3):1020-1025
45. Janknecht R, Nordheim A (1996) MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem Biophys Res Commun 228(3):831-837. doi: 10.1006/bbrc.1996.1740
46. Feng XH, Zhang Y, Wu RY, Derynck R (1998) The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 12(14):2153-2163
47. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M (1998) Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17(11):2994-3004. doi: 10.1093/emboj/17.11. 2994
48. Ait-Si-Ali S, Polesskaya A, Filleur S, Ferreira R, Duquet A, Robin P, Vervish A, Trouche D, Cabon F, Harel-Bellan A (2000) CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 19(20):2430-2437. doi: 10.1038/sj.onc.1203562
49. Denis CM, Chitayat S, Plevin MJ, Wang F, Thompson P, Liu S, Spencer HL, Ikura M, Lebrun DP, Smith SP (2012) Structural basis of CBP/p300 recruitment in leukemia induction by E2A-PBX1. Blood 120(19):3968-3977. doi: 10.1182/blood-2012-02-411397
50. Teufel DP, Freund SM, Bycroft M, Fersht AR (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci USA 104(17):7009-7014. doi: 10.1073/pnas.0702010104
51. Wang F, Marshall CB, Yamamoto K, Li GY, Gasmi-Seabrook GM, Okada H, Mak TW, Ikura M (2012) Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment. Proc Natl Acad Sci USA 109(16):6078-6083. doi: 10.1073/pnas. 1119073109
52. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM (1996) Role of CBP/P300 in nuclear receptor signalling. Nature 383(6595):99-103. doi: 10.1038/383099a0
53. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F (1998) CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273(48):31853-31859
54. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M (1996) p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 93(21):11540-11545
55. Kee BL, Arias J, Montminy MR (1996) Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J Biol Chem 271(5):2373-2375
56. Nakajima T, Uchida C, Anderson SF, Lee CG, Hurwitz J, Parvin JD, Montminy M (1997) RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90(6):1107-1112. doi: S0092-8674(00)80376-1
57. Cho H, Orphanides G, Sun X, Yang XJ, Ogryzko V, Lees E, Nakatani Y, Reinberg D (1998) A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol 18(9):5355-5363
58. Kim TK, Kim TH, Maniatis T (1998) Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-beta enhanceosome in vitro. Proc Natl Acad Sci USA 95(21):12191-12196
59. Swope DL, Mueller CL, Chrivia JC (1996) CREB-binding protein activates transcription through multiple domains. J Biol Chem 271(45):28138-28145
60. Felzien LK, Farrell S, Betts JC, Mosavin R, Nabel GJ (1999) Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common domain of the p300 coactivator. Mol Cell Biol 19(6):4241-4246
61. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H (1997) Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7(9):689-692. doi: S0960-9822(06)00296-X
62. Nagy Z, Tora L (2007) Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26(37):5341-5357. doi: 10.1038/sj.onc.1210604
63. Zeng L, Zhang Q, Gerona-Navarro G, Moshkina N, Zhou MM (2008) Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. Structure 16(4):643-652. doi: 10.1016/j.str.2008.01.010
64. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY, Ge K (2011) Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 30(2):249-262. doi: 10.1038/emboj.2010.318
65. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K (1998) The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 12(11):1638-1651
66. Paulson M, Press C, Smith E, Tanese N, Levy DE (2002) IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol 4(2):140-147. doi: 10.1038/ncb747
67. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y (1996) A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382(6589):319-324. doi: 10.1038/382319a0
68. Hosoda H, Kato K, Asano H, Ito M, Kato H, Iwamoto T, Suzuki A, Masushige S, Kida S (2009) CBP/p300 is a cell type-specific modulator of CLOCK/BMAL1-mediated transcription. Mol Brain 2:34. doi: 10.1186/1756-6606-2-34
69. Xu W, Edmondson DG, Roth SY (1998) Mammalian GCN5 and P/CAF acetyltransferases have homologous amino-terminal domains important for recognition of nucleosomal substrates. Mol Cell Biol 18(10):5659-5669
70. Kahata K, Hayashi M, Asaka M, Hellman U, Kitagawa H, Yanagisawa J, Kato S, Imamura T, Miyazono K (2004) Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5. Genes Cells 9(2):143-151. doi: 706
71. Phan HM, Xu AW, Coco C, Srajer G, Wyszomierski S, Evrard YA, Eckner R, Dent SY (2005) GCN5 and p300 share essential functions during early embryogenesis. Dev Dyn 233(4):1337-1347. doi: 10.1002/dvdy.20445
72. Michael LF, Asahara H, Shulman AI, Kraus WL, Montminy M (2000) The phosphorylation status of a cyclic AMP-responsive activator is modulated via a chromatin-dependent mechanism. Mol Cell Biol 20(5):1596-1603
73. Radhakrishnan I, Perez-Alvarado GC, Parker D, Dyson HJ, Montminy MR, Wright PE (1997) Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator: coactivator interactions. Cell 91(6):741-752. doi: S0092-8674(00)80463-8
74. Sugase K, Dyson HJ, Wright PE (2007) Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 447(7147):1021-1025. doi: 10.1038/nature05858
75. Solt I, Magyar C, Simon I, Tompa P, Fuxreiter M (2006) Phosphorylation-induced transient intrinsic structure in the kinase-inducible domain of CREB facilitates its recognition by the KIX domain of CBP. Proteins 64(3):749-757. doi: 10.1002/prot.21032
76. Turjanski AG, Gutkind JS, Best RB, Hummer G (2008) Binding-induced folding of a natively unstructured transcription factor. PLoS Comput Biol 4(4):e1000060. doi: 10.1371/journal.pcbi.1000060
77. Zor T, Mayr BM, Dyson HJ, Montminy MR, Wright PE (2002) Roles of phosphorylation and helix propensity in the binding of the KIX domain of CREB-binding protein by constitutive (c-Myb) and inducible (CREB) activators. J Biol Chem 277(44):42241-42248. doi: 10.1074/jbc.M207361200
78. Zor T, De Guzman RN, Dyson HJ, Wright PE (2004) Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. J Mol Biol 337(3):521-534. doi: 10.1016/j.jmb.2004.01.038
79. Goto NK, Zor T, Martinez-Yamout M, Dyson HJ, Wright PE (2002) Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain. J Biol Chem 277(45):43168-43174. doi: 10.1074/jbc.M207660200
80. De Guzman RN, Goto NK, Dyson HJ, Wright PE (2006) Structural basis for cooperative transcription factor binding to the CBP coactivator. J Mol Biol 355(5):1005-1013. doi: 10.1016/j.jmb.2005.09.059
81. Steegenga WT, van Laar T, Riteco N, Mandarino A, Shvarts A, van der Eb AJ, Jochemsen AG (1996) Adenovirus E1A proteins inhibit activation of transcription by p53. Mol Cell Biol 16(5):2101-2109
82. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL, Halazonetis TD (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 57(17):3693-3696
83. Wang F, Marshall CB, Li GY, Yamamoto K, Mak TW, Ikura M (2009) Synergistic interplay between promoter recognition and CBP/p300 coactivator recruitment by FOXO3a. ACS Chem Biol 4(12):1017-1027. doi: 10.1021/cb900190u
84. Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry 48(10):2115-2124. doi: 10.1021/bi802055v
85. Cook PR, Polakowski N, Lemasson I (2011) HTLV-1 HBZ protein deregulates interactions between cellular factors and the KIX domain of p300/CBP. J Mol Biol 409(3):384-398. doi: 10.1016/j.jmb.2011.04.003
86. Campbell KM, Lumb KJ (2002) Structurally distinct modes of recognition of the KIX domain of CBP by Jun and CREB. Biochemistry 41(47):13956-13964. doi: bi026222m
87. Lee YH, Bedford MT, Stallcup MR (2011) Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation. Genes Dev 25(2):176-188. doi: 10.1101/gad.1975811
88. Bayly R, Chuen L, Currie RA, Hyndman BD, Casselman R, Blobel GA, LeBrun DP (2004) E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. J Biol Chem 279(53):55362-55371. doi: 10.1074/jbc.M408654200
89. Hyndman BD, Thompson P, Bayly R, Cote GP (1819) Lebrun DP (2012) E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300. Biochim Biophys Acta 5:446-453. doi: 10.1016/j.bbagrm.2012.02.009
90. Ramirez JA, Nyborg JK (2007) Molecular characterization of HTLV-1 Tax interaction with the KIX domain of CBP/p300. J Mol Biol 372(4):958-969. doi: 10.1016/j.jmb.2007.06.062
91. Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R (1996) SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev 10(22):2903-2911
92. Plevin MJ, Mills MM, Ikura M (2005) The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci 30(2):66-69. doi: 10.1016/j.tibs.2004.12.001
93. De Guzman RN, Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE (2005) CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. Biochemistry 44(2):490-497. doi: 10.1021/bi048161t
94. Legge GB, Martinez-Yamout MA, Hambly DM, Trinh T, Lee BM, Dyson HJ, Wright PE (2004) ZZ domain of CBP: an unusual zinc finger fold in a protein interaction module. J Mol Biol 343(4):1081-1093. doi: 10.1016/j.jmb.2004.08.087
95. Miller M, Dauter Z, Cherry S, Tropea JE, Wlodawer A (2009) Structure of the Taz2 domain of p300: insights into ligand binding. Acta Crystallogr D Biol Crystallogr 65(Pt 12):1301-1308. doi: 10.1107/S0907444909040153
96. Kalkhoven E, Teunissen H, Houweling A, Verrijzer CP, Zantema A (2002) The PHD type zinc finger is an integral part of the CBP acetyltransferase domain. Mol Cell Biol 22(7):1961-1970
97. Zeng L, Yap KL, Ivanov AV, Wang X, Mujtaba S, Plotnikova O, Rauscher FJ 3rd, Zhou MM (2008) Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing. Nat Struct Mol Biol 15(6):626-633. doi: 10.1038/nsmb.1416
98. Lallous N, Legrand P, McEwen AG, Ramon-Maiques S, Samama JP, Birck C (2011) The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers. PLoS ONE 6(11):e27599. doi: 10.1371/journal.pone. 0027599
99. Ruas JL, Poellinger L, Pereira T (2005) Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 118(Pt 2):301-311. doi: 10.1242/jcs.01617
100. Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc Natl Acad Sci USA 106(16):6591-6596. doi: 10.1073/pnas.0811023106
101. Feng H, Jenkins LM, Durell SR, Hayashi R, Mazur SJ, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Bai Y (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17(2):202-210. doi: 10.1016/j.str.2008.12.009
102. Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Mazur SJ (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48(6):1244-1255. doi: 10.1021/bi801716h
103. Arai M, Ferreon JC, Wright PE (2012) Quantitative analysis of multisite protein-ligand interactions by NMR: binding of intrinsically disordered p53 transactivation subdomains with the TAZ2 domain of CBP. J Am Chem Soc 134(8):3792-3803. doi: 10.1021/ja209936u
104. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE (2002) Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 99(8):5271-5276. doi: 10.1073/pnas.082121399
105. Yin Z, Haynie J, Yang X, Han B, Kiatchoosakun S, Restivo J, Yuan S, Prabhakar NR, Herrup K, Conlon RA, Hoit BD, Watanabe M, Yang YC (2002) The essential role of Cited2, a negative regulator for HIF-1alpha, in heart development and neurulation. Proc Natl Acad Sci USA 99(16):10488-10493. doi: 10.1073/pnas.162371799
106. De Guzman RN, Martinez-Yamout MA, Dyson HJ, Wright PE (2004) Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2: regulation by competition between intrinsically unstructured ligands for non-identical binding sites. J Biol Chem 279(4):3042-3049. doi: 10.1074/jbc.M310348200
107. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G, Eck MJ (2003) Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol 10(7):504-512. doi: 10.1038/nsb936
108. O'Connor MJ, Zimmermann H, Nielsen S, Bernard HU, Kouzarides T (1999) Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. J Virol 73(5):3574-3581
109. Kurokawa R, Kalafus D, Ogliastro MH, Kioussi C, Xu L, Torchia J, Rosenfeld MG, Glass CK (1998) Differential use of CREB binding protein-coactivator complexes. Science 279(5351):700-703
110. Fax P, Lipinski KS, Esche H, Brockmann D (2000) cAMP-independent activation of the adenovirus type 12 E2 promoter correlates with the recruitment of CREB-1/ATF-1, E1A(12S), and CBP to the E2-CRE. J Biol Chem 275(12):8911-8920
111. Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein. Proc Natl Acad Sci USA 106(32):13260-13265. doi: 10.1073/pnas.0906770106
112. Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains. EMBO J 28(7):948-958. doi: 10.1038/emboj.2009.30
113. McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27(1):40-47. doi: S0968-0004(01)02031-X
114. Sartorelli V, Huang J, Hamamori Y, Kedes L (1997) Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 17(2):1010-1026
115. Youn HD, Chatila TA, Liu JO (2000) Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J 19(16):4323-4331. doi: 10.1093/emboj/19.16.4323
116. Slepak TI, Webster KA, Zang J, Prentice H, O'Dowd A, Hicks MN, Bishopric NH (2001) Control of cardiac-specific transcription by p300 through myocyte enhancer factor-2D. J Biol Chem 276(10):7575-7585. doi: 10.1074/jbc.M004625200
117. He J, Ye J, Cai Y, Riquelme C, Liu JO, Liu X, Han A, Chen L (2011) Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly. Nucleic Acids Res 39(10):4464-4474. doi: 10.1093/nar/gkr030
118. Qin BY, Liu C, Srinath H, Lam SS, Correia JJ, Derynck R, Lin K (2005) Crystal structure of IRF-3 in complex with CBP. Structure 13(9):1269-1277. doi: 10.1016/j.str.2005.06.011
119. Lee CW, Martinez-Yamout MA, Dyson HJ, Wright PE (2010) Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry 49(46):9964-9971. doi: 10.1021/bi1012996
120. Chen D, Huang SM, Stallcup MR (2000) Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem 275(52):40810-40816. doi: 10.1074/jbc.M005459200
121. Demarest SJ, Deechongkit S, Dyson HJ, Evans RM, Wright PE (2004) Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB-binding protein. Protein Sci 13(1):203-210. doi: 10.1110/ps.03366504
122. Kjaergaard M, Teilum K, Poulsen FM (2010) Conformational selection in the molten globule state of the nuclear coactivator binding domain of CBP. Proc Natl Acad Sci USA 107(28):12535-12540. doi: 10.1073/pnas.1001693107
123. Hammes GG, Chang YC, Oas TG (2009) Conformational selection or induced fit: a flux description of reaction mechanism. Proc Natl Acad Sci USA 106(33):13737-13741. doi: 10.1073/pnas.0907195106
124. Moras D, Gronemeyer H (1998) The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10(3):384-391. doi: S0955-0674(98)80015-X
125. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387(6634):733-736. doi: 10.1038/42750
126. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6(3):197-208. doi: 10.1038/nrm1589
127. Mittag T, Kay LE, Forman-Kay JD (2010) Protein dynamics and conformational disorder in molecular recognition. J Mol Recognit 23(2):105-116. doi: 10.1002/jmr.961
128. Lee CW, Ferreon JC, Ferreon AC, Arai M, Wright PE (2010) Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc Natl Acad Sci USA 107(45):19290-19295. doi: 10.1073/pnas.1013078107
129. Mas C, Lussier-Price M, Soni S, Morse T, Arseneault G, Di Lello P, Lafrance-Vanasse J, Bieker JJ, Omichinski JG (2011) Structural and functional characterization of an atypical activation domain in erythroid Kruppel-like factor (EKLF). Proc Natl Acad Sci USA 108(26):10484-10489. doi: 10.1073/pnas.1017029108
130. Wang F, Marshall CB, Yamamoto K, Li GY, Plevin MJ, You H, Mak TW, Ikura M (2008) Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. J Mol Biol 384(3):590-603. doi: 10.1016/j.jmb.2008.09.025
131. You H, Yamamoto K, Mak TW (2006) Regulation of transactivation- independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci USA 103(24):9051-9056. doi: 10.1073/pnas.0600889103
132. Renault VM, Thekkat PU, Hoang KL, White JL, Brady CA, Kenzelmann Broz D, Venturelli OS, Johnson TM, Oskoui PR, Xuan Z, Santo EE, Zhang MQ, Vogel H, Attardi LD, Brunet A (2011) The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene 30(29):3207-3221. doi: 10.1038/onc.2011.35
133. Shuai K (2000) Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19(21):2638-2644. doi: 10.1038/sj.onc.1203522
134. Seoane J, Le HV, Shen L, Anderson SA, Massague J (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117(2):211-223. doi: S0092867404002983
135. Gotea V, Visel A, Westlund JM, Nobrega MA, Pennacchio LA, Ovcharenko I (2010) Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Res 20(5):565-577. doi: gr.10.1101/gr.104471.109
136. Bakker WJ, Harris IS, Mak TW (2007) FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 28(6):941-953. doi: 10.1016/j.molcel.2007.10.035
137. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS (2008) PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA 105(7):2622-2627. doi: 10.1073/pnas.0706790105
138. Xie H, Vucetic S, Iakoucheva LM, Oldfield CJ, Dunker AK, Obradovic Z,
139. 2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev 8(21):2527-2539
140. Shi Y, Venkataraman SL, Dodson GE, Mabb AM, LeBlanc S, Tibbetts RS (2004) Direct regulation of CREB transcriptional activity by ATM in response to genotoxic stress. Proc Natl Acad Sci USA 101(16):5898-5903. doi: 10.1073/pnas.0307718101
141. Shanware NP, Trinh AT, Williams LM, Tibbetts RS (2007) Coregulated ataxia telangiectasia-mutated and casein kinase sites modulate cAMP-response element-binding protein-coactivator interactions in response to DNA damage. J Biol Chem 282(9):6283-6291. doi: 10.1074/jbc.M610674200
142. Altarejos JY, Montminy M (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12(3):141-151. doi: 10.1038/nrm3072
143. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273(49):33048-33053
144. Teufel DP, Bycroft M, Fersht AR (2009) Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 28(20):2112-2118. doi: 10.1038/onc.2009.71
145. Cho H, Ahn DR, Park H, Yang EG (2007) Modulation of p300 binding by posttranslational modifications of the C-terminal activation domain of hypoxia-inducible factor-1alpha. FEBS Lett 581(8):1542-1548. doi: 10.1016/j.febslet.2007.03.015
146. Zanger K, Cohen LE, Hashimoto K, Radovick S, Wondisford FE (1999) A novel mechanism for cyclic adenosine 3′,5′-monophosphate regulation of gene expression by CREB-binding protein. Mol Endocrinol 13(2):268-275
147. Zhou XY, Shibusawa N, Naik K, Porras D, Temple K, Ou H, Kaihara K, Roe MW, Brady MJ, Wondisford FE (2004) Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med 10(6):633-637. doi: 10.1038/nm1050
148. Zanger K, Radovick S, Wondisford FE (2001) CREB binding protein recruitment to the transcription complex requires growth factor-dependent phosphorylation of its GF box. Mol Cell 7(3):551-558. doi: S1097-2765(01)00202-7
149. Banerjee T, Chakravarti D (2011) A peek into the complex realm of histone phosphorylation. Mol Cell Biol 31(24):4858-4873. doi: 10.1128/MCB.05631-11
150. Cheung P, Lau P (2005) Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 19(3):563-573. doi: 10.1210/me.2004-0496
151. Weake VM, Workman JL (2008) Histone ubiquitination: triggering gene activity. Mol Cell 29(6):653-663. doi: 10.1016/j.molcel.2008.02.014
152. Shiio Y, Eisenman RN (2003) Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA 100(23):13225-13230. doi: 10.1073/pnas.1735528100
153. Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75-100. doi: 10.1146/annurev.biochem.76.052705.162114
154. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074-1080. doi: 10.1126/science.1063127
155. Wang GG, Allis CD, Chi P (2007) Chromatin remodeling and cancer, Part I: covalent histone modifications. Trends Mol Med 13(9):363-372. doi: 10.1016/j.molmed.2007.07.003
156. Gorisch SM, Wachsmuth M, Toth KF, Lichter P, Rippe K (2005) Histone acetylation increases chromatin accessibility. J Cell Sci 118(Pt 24):5825-5834. doi: 10.1242/jcs.02689
157. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani Y (1999) Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J Biol Chem 274(3):1189-1192
158. Das C, Lucia MS, Hansen KC, Tyler JK (2009) CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459(7243):113-117. doi: 10.1038/nature07861
159. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451(7180):846-850. doi: 10.1038/nature06546
160. Wang L, Tang Y, Cole PA, Marmorstein R (2008) Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol 18(6):741-747. doi: 10.1016/j.sbi.2008.09.004
161. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y, Evans RM (1999) A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96(3):393-403. doi: S0092-8674(00)80552-8
162. MacLellan WR, Xiao G, Abdellatif M, Schneider MD (2000) A novel Rb- and p300-binding protein inhibits transactivation by MyoD. Mol Cell Biol 20(23):8903-8915
163. Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG Jr (2000) Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol 20(23):8889-8902
164. Liu R, Lei JX, Luo C, Lan X, Chi L, Deng P, Lei S, Ghribi O, Liu QY (2012) Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease. Neurobiol Dis 45(3):902-912. doi: 10.1016/j.nbd.2011.12.007
165. Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, Sanchez R, Zeleznik-Le NJ, Ronai Z, Zhou MM (2004) Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 13(2):251-263. doi: S1097276503005288
166. Gu W, Shi XL, Roeder RG (1997) Synergistic activation of transcription by CBP and p53. Nature 387(6635):819-823. doi: 10.1038/42972
167. Ma K, Chan JK, Zhu G, Wu Z (2005) Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol Cell Biol 25(9):3575-3582. doi: 10.1128/MCB.25.9.3575-3582.2005
168. Tu AW, Luo K (2007) Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. J Biol Chem 282(29):21187-21196. doi: 10.1074/jbc.M700085200
169. Lu Q, Hutchins AE, Doyle CM, Lundblad JR, Kwok RP (2003) Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription. J Biol Chem 278(18):15727-15734. doi: 10.1074/jbc.M300546200
170. Hyndman BD, Thompson P, Denis CM, Chitayat S, Bayly R, Smith SP (1819) Lebrun DP (2012) Mapping acetylation sites in E2A identifies a conserved lysine residue in activation domain 1 that promotes CBP/p300 recruitment and transcriptional activation. Biochim Biophys Acta 5:375-381. doi: 10.1016/j.bbagrm.2011.11.013
171. van der Heide LP, Smidt MP (2005) Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci 30(2):81-86. doi: 10.1016/j.tibs.2004.12.002
172. Perrot V, Rechler MM (2005) The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol Endocrinol 19(9):2283-2298. doi: 10.1210/me.2004-0292
173. Waltzer L, Bienz M (1998) Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395(6701):521-525. doi: 10.1038/26785
174. Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome. Am J Dis Child 105:588-608
175. Blough RI, Petrij F, Dauwerse JG, Milatovich-Cherry A, Weiss L, Saal HM, Rubinstein JH (2000) Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am J Med Genet 90(1):29-34. doi: 10.1002/(SICI)1096-8628(20000103)90: 1<29:AID-AJMG6>3.0.CO;2-Z
176. Petrij F, Dorsman JC, Dauwerse HG, Giles RH, Peeters T, Hennekam RC, Breuning MH, Peters DJ (2000) Rubinstein-Taybi syndrome caused by a De Novo reciprocal translocation t(2;16)(q36.3;p13.3). Am J Med Genet 92(1):47-52. doi: 10.1002/(SICI)1096-8628(20000501)92:1<47:AID-AJMG8>3.0.CO;2-H
177. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, Yao TP (2000) Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14(3):272-277
178. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL (2009) Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood 114(23):4804-4812. doi: 10.1182/blood-2009-04-217794
179. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298-303. doi: 10.1038/nature10351
180. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14(1):33-41. doi: 10.1038/ng0996-33
181. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ (2000) MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 28(2):138-144. doi: 10.1002/(SICI)1098- 2264(200006)28:2<138:AID-GCC2>3.0.CO;2-2
182. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A, Maseki N, Kaneko Y (1997) Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosomes Cancer 20(1):60-63. doi: 10.1002/(SICI)1098-2264(199709)20:1<60: AID-GCC9>3.0.CO;2-7
183. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 94(16):8732-8737
184. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N (1997) All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90(2):535-541
185. Taki T, Sako M, Tsuchida M, Hayashi Y (1997) The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89(11):3945-3950
186. Lavau C, Du C, Thirman M, Zeleznik-Le N (2000) Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19(17):4655-4664. doi: 10.1093/emboj/19.17.4655
187. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ (2003) p300 in prostate cancer proliferation and progression. Cancer Res 63(22):7638-7640
188. Ianculescu I, Wu DY, Siegmund KD, Stallcup MR (2012) Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem 287(6):4000-4013. doi: 10.1074/jbc.M111.300194
189. Ionov Y, Matsui S, Cowell JK (2004) A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci USA 101(5):1273-1278. doi: 10.1073/pnas.0307276101
190. Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Tanaka S, Kuroiwa K, Eto M, Naito S (2012) p300 mediates cellular resistance to doxorubicin in bladder cancer. Mol Med Rep 5(1):173-176. doi: 10.3892/mmr.2011.593
191. Hao S, He W, Li Y, Ding H, Hou Y, Nie J, Hou FF, Kahn M, Liu Y (2011) Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 22(9):1642-1653. doi: 10.1681/ASN.2010101079
192. Zhou B, Liu Y, Kahn M, Ann DK, Han A, Wang H, Nguyen C, Flodby P, Zhong Q, Krishnaveni MS, Liebler JM, Minoo P, Crandall ED, Borok Z (2012) Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem 287(10):7026-7038. doi: 10.1074/jbc.M111.276311
193. Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D, Liu H, Zhao Y, Radich J, Kahn M (2011) The gamma catenin/CBP complex maintains survivin transcription in beta-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 11(2):213-225. doi: EPub-Abstract-CCDT-97
194. Marzio G, Tyagi M, Gutierrez MI, Giacca M (1998) HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 95(23):13519-13524
195. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S (2010) CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 107(52):22687-22692. doi: 10.1073/pnas.1012851108
196. Stanojevic V, Habener JF, Thomas MK (2004) Pancreas duodenum homeobox-1 transcriptional activation requires interactions with p300. Endocrinology 145(6):2918-2928. doi: 10.1210/en.2003-1188
197. Chen G, Zhu J, Lv T, Wu G, Sun H, Huang X, Tian J (2009) Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts. J Biomed Sci 16:24. doi: 10.1186/1423-0127-16-24
198. Wei JQ, Shehadeh LA, Mitrani JM, Pessanha M, Slepak TI, Webster KA, Bishopric NH (2008) Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 118(9):934-946. doi: 10.1161/CIRCULATIONAHA. 107.760488
199. Lee LW, Mapp AK (2010) Transcriptional switches: chemical approaches to gene regulation. J Biol Chem 285(15):11033-11038. doi: 10.1074/jbc.R109.075044
200. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279(49):51163-51171. doi: 10.1074/jbc.M409024200
201. Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12(3):332-347. doi: BSP/CDT/E-Pub/00185
202. Mantelingu K, Reddy BA, Swaminathan V, Kishore AH, Siddappa NB, Kumar GV, Nagashankar G, Natesh N, Roy S, Sadhale PP, Ranga U, Narayana C, Kundu TK (2007) Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 14(6):645-657. doi: 10.1016/j.chembiol. 2007.04.011
203. Arif M, Pradhan SK, Thanuja GR, Vedamurthy BM, Agrawal S, Dasgupta D, Kundu TK (2009) Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J Med Chem 52(2):267-277. doi: 10.1021/jm800657z
204. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA, Culig Z (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10(9):1644-1655. doi: 10.1158/1535-7163.MCT-11-0182
205. Filippakopoulos P, Knapp S (2012) The bromodomain interaction module. FEBS Lett 586(17):2692-2704. doi: 10.1016/j.febslet.2012.04.045
206. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1):214-231. doi: 10.1016/j.cell.2012.02.013
207. Chen J, Ghazawi FM, Li Q (2010) Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes. Epigenetics 5(6):509-515. doi: 12224
208. Borah JC, Mujtaba S, Karakikes I, Zeng L, Muller M, Patel J, Moshkina N, Morohashi K, Zhang W, Gerona-Navarro G, Hajjar RJ, Zhou MM (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 18(4):531-541. doi: 10.1016/j.chembiol.2010.12.021
209. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Vuppusetty C, Marsden B, Knapp S, Conway SJ, Heightman TD (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54(19):6761-6770. doi: 10.1021/jm200640v
210. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1):33-43. doi: 10.1016/j.ccr.2004.06.009
211. Block KM, Wang H, Szabo LZ, Polaske NW, Henchey LK, Dubey R, Kushal S, Laszlo CF, Makhoul J, Song Z, Meuillet EJ, Olenyuk BZ (2009) Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J Am Chem Soc 131(50):18078-18088. doi: 10.1021/ja807601b
212. Best JL, Amezcua CA, Mayr B, Flechner L, Murawsky CM, Emerson B, Zor T, Gardner KH, Montminy M (2004) Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci USA 101(51):17622-17627. doi: 10.1073/pnas.0406374101
213. Li BX, Xiao X (2009) Discovery of a small-molecule inhibitor of the KIX-KID interaction. ChemBioChem 10(17):2721-2724. doi: 10.1002/cbic.200900552
214. Buhrlage SJ, Bates CA, Rowe SP, Minter AR, Brennan BB, Majmudar CY, Wemmer DE, Al-Hashimi H, Mapp AK (2009) Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. ACS Chem Biol 4(5):335-344. doi: 10.1021/cb900028j
215. Majmudar CY, Hojfeldt JW, Arevang CJ, Pomerantz WC, Gagnon JK, Schultz PJ, Cesa LC, Doss CH, Rowe SP, Vasquez V, Tamayo-Castillo G, Cierpicki T, Brooks CL 3rd, Sherman DH, Mapp AK (2012) Sekikaic Acid and Lobaric Acid Target a Dynamic Interface of the Coactivator CBP/p300. Angew Chem Int Ed Engl 51(45):11258-11262. doi: 10.1002/anie.201206815
216. Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman M, Nicolaou KC, Van Meir EG (2012) Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1alpha interaction with co-factors p300/CBP. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-12-0861
217. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT (2004) Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 337(3):635-645. doi: 10.1016/j.jmb.2004.02.002